1. Scrip
  2. >>Focus On Asia
  3. >>India

Indian biosimilars guidelines go on stream amid implementation concerns

 
• By Anju Ghangurde

India is set to implement its first set of guidelines on biosimilars next month, lending much-needed clarity to the approval pathway for such products, though concerns persist on whether the country's regulatory machinery is geared to implement these effectively.

India is set to implement its first set of guidelines on biosimilars next month, lending much-needed clarity to the approval pathway for such products, though concerns persist on whether the country's regulatory machinery is geared to implement these effectively.

The guidelines, which outline the data requirements for the production, characterisation, preclinical and clinical trials for the marketing approval of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By Vibha Ravi

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.

US Weaponization Of Trade – India’s Red Lines And Keeping Pharma Insulated

 
• By Anju Ghangurde

As US-India ties rupture, what could it mean for joint calls by the two nations to de-risk the pharma supply chain and could New Delhi consider non-tariff tools to make a point?

GSK India Oncology Second Innings: Can Jemperli, Zejula Set The Pace?

 
• By Anju Ghangurde

GSK recommits to oncology in India with the debut of Jemperli and Zejula, backed by a tiered pricing approach, patient support program and efforts to address unmet needs in the biomarker ecosystem. Can it widen treatment access materially?

OneSource CEO On Next-Gen GLP-1 Innovator Talks, Xbrane And Viatris Partnering

 
• By Vibha Ravi

OneSource Specialty CEO Neeraj Sharma discusses with Scrip exploratory talks with next-gen GLP-1 innovators, prospects for semaglutide generics and investment in Swedish firm Xbrane, among other topics.

More from Focus On Asia

Mitsubishi Tanabe Names New CEO In C-Suite Reshuffle

 
• By Lisa Takagi

Under new owner Bain Capital, the Japanese firm is aiming to regain its global presence, helped by new top executives formerly with Pfizer Japan and Takeda.

DualityBio Eyes 1L Use For ADC Combos With BioNTech’s Bispecific

 
• By Dexter Jie Yan

Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.

Nippon Kayaku Aims To Broaden Portfolio Via Singaporean JV

 
• By Lisa Takagi

Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.